Clinical Focus

Previous Articles     Next Articles

Antiatherosclerosis effect of sitagliptin in patients with type 2 diabetes mellitus

  

  1. 1.Department of Cardiology, Beijing Haidian Hospital, Beijing 100080, China;
    2.Department of Geriatric Medicine,  Peking University Third Hospital, Beijing 100191, China
  • Online:2016-09-05 Published:2016-08-31
  • Contact: Corresponding author: Guo Yunfei,Email: 13520234261@163.com

Abstract: ObjectiveTo explore the effect of sitagliptin, a dipeptidyl peptidase 4 inhibitor, on carotid intimamedia thickness (IMT)in insulintreated patients with type 2 diabetes mellitus (T2DM). MethodsThis prospective, randomized, parallel group and comparative study included 172 insulintreated patients with T2DM who were randomly allocated to either the sitagliptin group (n=84) or the control group (n=88). The primary outcomes were changes in mean IMT of the carotid artery measured by echography at the end of a 12months′  treatment. ResultsChanges in the mean IMT of the carotid arteries were significantly greater after sitagliptin treatment compared with conventional treatment (P<0.05). After followup of 12 months, sitagliptin, but not conventional treatment, significantly reduced the mean IMT of carotid arteries relative to the baseline. Sitagliptin had a more potent glucoselowering effect compared with the conventional treatment (P<0.05), without increasing hypoglycemic episodes or body mass. ConclusionSitagliptin attenuated the progression of carotid IMT in insulintreated T2DM patients with glucoselowering effect.

Key words: diabetes mellitus, type 2; atherosclerosis;dipeptidylpeptidase Ⅳ inhibitors;carotid intimamedia , thickness